Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Changes in dendritic microstructure and clinical improvement with repetitive Transcranial Magnetic Stimulation for major depression

EF 2019-20

Résumé
"Major Depressive Disorder (MDD) is a leading cause of disability world-wide. Though current medication and psychotherapy treatments are effective, many patients do not improve. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation treatment for such individuals. rTMS uses magnetic fields to stimulate specific regions of the cerebral cortex and by delivering specific patterns of energy, leads to changes in the cortex. This involves functional and structural changes in neurons, through a process known as 'synaptic plasticity'. I propose to use a drug called d-cycloserine (DCS) to enhance rTMS' effects on synaptic plasticity. DCS has been safely used in other psychiatric disorders to enhance synaptic plasticity-dependent treatments. In addition to the antidepressant effects of combining these strategies, I will use advanced magnetic resonance imaging (MRI) techniques to capture microscopic structural changes as participants receive treatment. This imaging technique is called 'neurite orientation dispersion and density' imaging, or NODDI for short. Using a randomized placebo-controlled design, participants with MDD will receive either a placebo capsule or DCS in conjunction with ten daily rTMS treatments. At the start of the trial, important clinical characteristics will be measured, and participants will have an MRI for NODDI. These will be repeated at the conclusion of the study. My study will directly test a novel strategy for improving patient outcomes in MDD, a common and debilitating illness where currently available treatments are often inadequate. Further, I will learn and apply advanced neuroscience skills to not only test the clinical efficacy of the strategy but understand its mechanism so that it can be further refined. "
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
429055
Name
Sohn Myren N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Changes in dendritic microstructure and clinical improvement with repetitive Transcranial Magnetic Stimulation for major depression
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Outcomes; Major Depressive Disorder; Mental Health; Neuroimaging; Synaptic Plasticity; Transcranial Magnetic Stimulation
Abstract
"Major Depressive Disorder (MDD) is a leading cause of disability world-wide. Though current medication and psychotherapy treatments are effective, many patients do not improve. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neurostimulation treatment for such individuals. rTMS uses magnetic fields to stimulate specific regions of the cerebral cortex and by delivering specific patterns of energy, leads to changes in the cortex. This involves functional and structural changes in neurons, through a process known as 'synaptic plasticity'. <span style=white-space:pre;> I propose to use a drug called d-cycloserine (DCS) to enhance rTMS' effects on synaptic plasticity. DCS has been safely used in other psychiatric disorders to enhance synaptic plasticity-dependent treatments. In addition to the antidepressant effects of combining these strategies, I will use advanced magnetic resonance imaging (MRI) techniques to capture microscopic structural changes as participants receive treatment. This imaging technique is called 'neurite orientation dispersion and density' imaging, or NODDI for short. <span style=white-space:pre;> Using a randomized placebo-controlled design, participants with MDD will receive either a placebo capsule or DCS in conjunction with ten daily rTMS treatments. At the start of the trial, important clinical characteristics will be measured, and participants will have an MRI for NODDI. These will be repeated at the conclusion of the study. My study will directly test a novel strategy for improving patient outcomes in MDD, a common and debilitating illness where currently available treatments are often inadequate. Further, I will learn and apply advanced neuroscience skills to not only test the clinical efficacy of the strategy but understand its mechanism so that it can be further refined. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sohn, Myren N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~